Chris Schott
Stock Analyst at J.P. Morgan
(4.43)
# 1,166
Out of 5,055 analysts
636
Total ratings
58.7%
Success rate
6.3%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgraded: Buy | $210 → $300 | $232.83 | +28.85% | 21 | Oct 12, 2026 | |
| TLV: TEVA Teva Pharmaceutical Industries Limited | Reiterated: Buy | ILA 15,378 | ILA 12,940 | +18.84% | 2 | Oct 11, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,500 | $1,208.74 | +24.10% | 75 | Oct 9, 2026 | |
| PFE Pfizer | Rated: Hold | $28 → $30 | $29.21 | +2.70% | 92 | Oct 9, 2026 | |
| ABBV AbbVie | Rated: Buy | $285 → $300 | $283.48 | +5.83% | 40 | Oct 8, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $73 | $59.28 | +23.14% | 43 | Oct 8, 2026 | |
| GILD Gilead Sciences | Reiterated: Buy | $160 → $170 | $153.54 | +10.72% | 35 | Oct 7, 2026 | |
| REGN Regeneron Pharmaceuticals | Rated: Buy | $900 → $950 | $778.36 | +22.05% | 34 | Oct 6, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $165 | $147.37 | +11.96% | 37 | Oct 5, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Hold | $270 → $285 | $253.91 | +12.24% | 22 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $18.90 | - | 21 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $22.55 | - | 23 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 → $62 | $58.99 | +5.10% | 10 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 | $17.44 | +3.21% | 29 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $130 → $115 | $75.29 | +52.74% | 16 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $300 → $350 | $426.11 | -17.86% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $15 | $15.95 | -5.96% | 31 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 → $11 | $13.74 | -19.94% | 13 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $675 → $775 | $529.01 | +46.50% | 15 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 → $8 | $1.05 | n/a | 9 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.40 | n/a | 41 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.97 | n/a | 3 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €85.68 → €87.47 | €141.90 | n/a | 2 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $43 → $54 | $36.40 | n/a | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $0.188 | n/a | 3 | Nov 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.61 | n/a | 1 | Oct 17, 2013 |
Biogen
Oct 12, 2026
Upgraded: Buy
Price Target: $210 → $300
Current: $232.83
Upside: +28.85%
Teva Pharmaceutical Industries Limited
Oct 11, 2026
Reiterated: Buy
Price Target: ILA 15,378
Current: ILA 12,940
Upside: +18.84%
Eli Lilly and Company
Oct 9, 2026
Reiterated: Buy
Price Target: $1,500
Current: $1,208.74
Upside: +24.10%
Pfizer
Oct 9, 2026
Rated: Hold
Price Target: $28 → $30
Current: $29.21
Upside: +2.70%
AbbVie
Oct 8, 2026
Rated: Buy
Price Target: $285 → $300
Current: $283.48
Upside: +5.83%
Bristol-Myers Squibb Company
Oct 8, 2026
Reiterated: Buy
Price Target: $73
Current: $59.28
Upside: +23.14%
Gilead Sciences
Oct 7, 2026
Reiterated: Buy
Price Target: $160 → $170
Current: $153.54
Upside: +10.72%
Regeneron Pharmaceuticals
Oct 6, 2026
Rated: Buy
Price Target: $900 → $950
Current: $778.36
Upside: +22.05%
Merck & Co.
Oct 5, 2026
Reiterated: Buy
Price Target: $165
Current: $147.37
Upside: +11.96%
Johnson & Johnson
Sep 29, 2026
Reiterated: Hold
Price Target: $270 → $285
Current: $253.91
Upside: +12.24%
Sep 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $18.90
Upside: -
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $22.55
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: $58 → $62
Current: $58.99
Upside: +5.10%
Aug 10, 2026
Reiterated: Hold
Price Target: $18
Current: $17.44
Upside: +3.21%
Aug 10, 2026
Reiterated: Buy
Price Target: $130 → $115
Current: $75.29
Upside: +52.74%
Aug 6, 2026
Reiterated: Hold
Price Target: $300 → $350
Current: $426.11
Upside: -17.86%
Feb 27, 2026
Reiterated: Hold
Price Target: $18 → $15
Current: $15.95
Upside: -5.96%
Feb 13, 2026
Reiterated: Sell
Price Target: $12 → $11
Current: $13.74
Upside: -19.94%
Nov 3, 2025
Reiterated: Buy
Price Target: $675 → $775
Current: $529.01
Upside: +46.50%
May 25, 2023
Reiterated: Hold
Price Target: $9 → $8
Current: $1.05
Upside: n/a
Jul 28, 2022
Downgraded: Hold
Price Target: n/a
Current: $8.40
Upside: n/a
May 19, 2020
Downgraded: Hold
Price Target: n/a
Current: $1.97
Upside: n/a
Mar 9, 2020
Reiterated: Buy
Price Target: €85.68 → €87.47
Current: €141.90
Upside: n/a
Feb 20, 2020
Reiterated: Hold
Price Target: $43 → $54
Current: $36.40
Upside: n/a
May 13, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Nov 17, 2017
Reiterated: Buy
Price Target: $35
Current: $0.188
Upside: n/a
Oct 17, 2013
Downgraded: Hold
Price Target: n/a
Current: $11.61
Upside: n/a